Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
zAvatar-Guided Therapy vs Standard of Care in Relapsed Ovarian and Metastatic Breast Cancer
2023-509598-22-01Phase 4Authorised
- Sponsor
- Rita Fior, Champalimaud Clinical Centre, Rita Fior
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of gemcitabine, capecitabine, alpelisib, abemaciclib, everolimus and 23 more in High-Grade Serous Ovarian Cancer (HGSOC), Endometrioid Cystadenocarcinoma and breast cancer (2 arms), sponsored by Rita Fior, Champalimaud Clinical Centre, Rita Fior. Primary endpoints: Progression-free survival in relapsed ovarian cancer and Progression-free survival in metastatic breast cancer. Planned start Nov 2024; status: authorised.
02
Drugs
gemcitabinecapecitabinealpelisibabemaciclibeverolimus
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)Endometrioid Cystadenocarcinomabreast cancer
Beyond the preview
Go deeper on 2023-509598-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509598-22-01.